Q32 Bio Inc. announced the appointment of Lee Kalowski as President. Mr. Kalowski brings over 20 years of biopharmaceutical experience with a focus on strategy, raising capital, and financial operations. Prior to joining Q32 Bio, Mr. Kalowski served as President and Chief Financial Officer of Bicycle Therapeutics where he led strategic finance and operations and oversaw the company's transition to a public clinical-stage biotech company.

While at Bicycle, Mr. Kalowskiled the IPO in 2019 and helped raise $1 Billion in total, including over $700 Million in private, public and non-dilutive financings. Prior to Bicycle, Mr. Kalowski was Chief Financial Officer of Tokai Pharmaceuticals where he helped lead the company's IPO in 2014. Earlier, Mr. Kalowski served in global biotechnology equity research as a Senior Analyst at Credit Suisse covering companies in the biopharmaceutical industry.

Mr. Kalowskireceived a B.A. in Biology and Economics from Union College and an MBA from The Wharton School of the University of Pennsylvania. Mr. Kalowski is currently a board member of Aro Biotherapeutics.